Not medical advice. This page explains what published drug labels and studies say, in plain language. It does not tell you whether to take, start, stop, skip, or change any medicine, and it gives no doses. Those decisions belong to you and your prescriber or pharmacist.
Metformin is one of the most commonly prescribed medicines for type 2 diabetes, and it is also one of the most misunderstood. People hear that it is “safe,” or that it is “hard on the kidneys,” or that it causes stomach trouble, and each claim is partly true and partly missing context. This guide walks through what the official prescribing label says, in plain language, so you can walk into an appointment with better questions.
Quick answer: Metformin is a prescription medicine used with diet and exercise to improve blood sugar control in type 2 diabetes. According to the label I read, it works mainly by reducing how much glucose the liver releases, reducing how much glucose is absorbed from the gut, and helping the body respond better to its own insulin. Stomach side effects are common. A rare but serious problem called lactic acidosis carries a boxed warning, and kidney function matters a great deal. It can lower vitamin B12 over time. Every decision about whether to take it, what form to take, or what to do around surgery, scans, illness or pregnancy belongs to your prescriber and pharmacist, not to a website.
This guide comes from Metabolic Clarity Labs, not from a doctor or pharmacist. The sources were read directly where possible, and the page says where one could not be opened. It leaves out doses on purpose.
What metformin is
Metformin belongs to a drug class called biguanides. It has been used for decades and comes as tablets, including immediate-release and extended-release versions. The label I read most closely is a current metformin hydrochloride tablet label on DailyMed (revised June 2026, from one generic manufacturer). Generic labels follow the same reference text, but individual products can differ in details, so the leaflet that comes with your own prescription is the one that applies to you.
The label says metformin is indicated “as an adjunct to diet and exercise to improve glycemic control in adults” with type 2 diabetes, and the same label describes a trial in young people aged 10 to 16, so pediatric use is also addressed in the document. “Adjunct” is the important word: the label frames the medicine as an addition to eating and activity patterns, not a replacement for them. If you want to see how food fits in, our diabetes food guide and diets compared page cover that side.
How it works, in plain language
The label’s mechanism section says metformin improves glucose tolerance in people with type 2 diabetes, lowering both fasting and after-meal glucose. It describes three actions: it reduces the amount of glucose the liver makes, it reduces how much glucose the intestine absorbs, and it improves insulin sensitivity by helping muscle and other tissue take up and use glucose. One detail surprises people: the label states that insulin secretion from the pancreas “remains unchanged,” and that fasting insulin and the all-day insulin response may actually go down. In other words, metformin does not work mainly by pushing the pancreas to release more insulin.
A clinical review chapter I read (Feingold, Endotext, updated December 29, 2025) puts the same idea in one sentence: metformin decreases hepatic (liver) glucose production and improves hepatic insulin sensitivity. That same chapter is also where the common-side-effect summary comes from: diarrhea, nausea and abdominal discomfort.
Why this matters in practice: because metformin does not force the pancreas to release insulin, the label says low blood sugar is uncommon when it is used by itself. The label and the Medication Guide still warn that the risk goes up when it is combined with insulin or with medicines that raise insulin release, with poor eating, or with alcohol. That is a question for your prescriber about your own combination.
What the studies behind the label found
Labels summarize the trials a manufacturer ran to win approval. They are useful, but they come from a specific group of people over a specific time, and they are not a promise about you.
The main placebo-controlled adult trial in the label I read was a double-blind, multicenter U.S. study in obese adults with type 2 diabetes not controlled by diet alone, lasting 29 weeks, with 141 people on metformin and 145 on placebo. The label reports that A1C changed by about -1.4% with metformin and +0.4% with placebo at the final visit, with starting averages of about 8.4% and 8.2%.
| What I did with the label numbers | Result |
|---|---|
| Difference between groups in A1C change | -1.4 minus (+0.4) = -1.8 percentage points |
| Rough group averages if you subtract the changes from the starting averages (my arithmetic) | Metformin group about 7.0%; placebo group about 8.6% |
| What this does not tell you | How you would respond. These are averages for one trial population over 29 weeks. |
The same label also lists a trial in which metformin was added to another diabetes drug (a sulfonylurea called glyburide) and a pediatric trial of up to 16 weeks in which the reported measure was fasting plasma glucose rather than A1C. The Endotext review describes a typical A1C reduction with metformin in the range of 1 to 2 percentage points and notes that, in the long-running UKPDS trial, metformin was associated with roughly a 40 percent reduction in cardiovascular disease, though the review author calls that suggestive and says larger outcome studies are needed. The label I read, for its part, says there is no conclusive evidence of macrovascular (heart and blood vessel) risk reduction from its own trials. Both statements can be true because they describe different bodies of evidence. This is a good place to ask your prescriber what applies to you.
I could not open the American Diabetes Association Standards of Care for this page, so I am not quoting what that document says about where metformin sits in a treatment plan. If you want that view, ask your prescriber how your plan lines up with current guidelines.
Common side effects, from the label
Stomach and gut effects are the best-known effects. The label’s adverse-reaction table comes from one U.S. trial in people with type 2 diabetes (141 on metformin, 145 on placebo). I computed the last column.
| Effect | On metformin | On placebo | Gap (my arithmetic) |
|---|---|---|---|
| Diarrhea | 53% | 12% | 41 points |
| Nausea or vomiting | 26% | 8% | 18 points |
| Flatulence (gas) | 12% | 6% | 6 points |
| Asthenia (weakness) | 9% | 6% | 3 points |
| Indigestion | 7% | 4% | 3 points |
| Abdominal discomfort | 6% | 5% | 1 point |
| Headache | 6% | 5% | 1 point |
Two cautions about this table. First, it describes an immediate-release product in a specific trial, and percentages differ from product to product and trial to trial. Second, the placebo column shows that some of these symptoms occur anyway. A sizeable gap, though, is exactly why many people bring up stomach side effects at appointments. The Medication Guide says the common effects are diarrhea, nausea and upset stomach, that they generally go away over time. It also says to tell your doctor if side effects are bothersome, last more than a few weeks, come back after going away, or start later in treatment. About 3 in 100 people report a temporary metallic taste, according to the same guide.
Extended-release products exist. The label’s pharmacology section notes that peak blood levels with the extended-release tablet are about 20 percent lower than with immediate-release, while overall absorption is comparable. Whether a different form makes sense for you is a prescriber and pharmacist conversation, and I am not suggesting one.
Serious warnings, quoted carefully
The label has a boxed warning, the strongest kind, for lactic acidosis. I want to state it carefully, because it is easy to either dismiss it or exaggerate it.
The boxed warning says postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension and resistant slow heart rhythms. It says onset is often subtle, with nonspecific symptoms such as malaise, muscle pain, respiratory distress, sleepiness and abdominal pain. It lists risk factors: kidney impairment, certain interacting drugs (for example topiramate and other carbonic anhydrase inhibitors), age 65 or older, iodinated contrast imaging, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. The Endotext chapter calls lactic acidosis “a very rare complication.”
| Warning topic | What the label says (short quotes or close paraphrase) | What to do with it |
|---|---|---|
| Lactic acidosis (boxed) | Rare, serious, often subtle at first. Risk factors listed above. | Ask your prescriber which of the risk factors apply to you. |
| Kidney function | Contraindicated when eGFR is below 30. Starting is not recommended with eGFR 30 to 45. Label says to obtain an eGFR at least annually. | Ask how often your kidney function should be checked. |
| Liver | “Avoid use” with clinical or laboratory evidence of hepatic disease. | Tell your prescriber about any liver history. |
| Contrast dye | Label says to stop at the time of or before an iodinated contrast imaging procedure, and recheck kidney function afterward in certain patients. | Tell the imaging team you take metformin; they and your prescriber decide. |
| Surgery and fasting | Label says it should be temporarily discontinued while food and fluid intake is restricted. | Ask your surgical team and prescriber for your plan. |
| Vitamin B12 | Label reports a drop to subnormal levels in about 7% of patients in trials. | See the labs section below and our B12 guides. |
| Low blood sugar | May increase the risk when combined with insulin or insulin secretagogues. | Ask how your other medicines fit. |
One more label statement belongs in this table. The label says metformin is contraindicated in acute or chronic metabolic acidosis, including diabetic ketoacidosis. The label also notes hypoxic states such as acute heart failure, shock, heart attack or sepsis as situations associated with lactic acidosis cases. Those are the situations where a hospital team, not a website, makes the decisions. If anyone around you has symptoms like those the Medication Guide describes (cold hands or feet, dizziness, a slow or irregular heartbeat, marked weakness, trouble breathing, sleepiness, or stomach pain with nausea or vomiting), the guide says to call your doctor right away. If it is an emergency, use emergency services.
Kidney function and the eGFR number
Many people first meet the term eGFR when metformin comes up. It is an estimate of how well your kidneys filter blood, reported on a lab panel. The label I read makes three points. It is contraindicated at eGFR below 30 mL/min/1.73 m². It says starting is not recommended when eGFR is between 30 and 45, and for people already taking it whose eGFR falls below 45, it says to assess the benefit and risk of continuing. And it says to obtain an eGFR at least annually, and more often in people at risk of kidney impairment, such as older adults. The label explains the reason: metformin is cleared by the kidneys, so accumulation and lactic acidosis risk increase with the degree of kidney impairment.
Questions worth bringing: Which eGFR value is in my chart? How often will it be checked? If my eGFR changes, who decides what happens to my medicines? Those are decisions only your prescriber can make with your complete record in front of them.
Vitamin B12: the long-term issue
The label states that in its trials a decrease to subnormal levels of previously normal serum B12 was observed in approximately 7 percent of patients. It recommends periodic monitoring; the monitoring section as summarized to me mentions yearly blood-count checks and B12 testing every two to three years, which I could not confirm line by line, so ask your prescriber what schedule applies to you. Risk factors are discussed in our metformin and B12 guide, and the testing cadence is covered in how often to check B12 on metformin. We also have a plain explanation of B12 deficiency symptoms with metformin and the tests used to look for it.
To put the number in perspective, about 7 in 100 people sounds small, but if a clinic follows 1,000 people on metformin for the trial-like timeframe, that works out to roughly 70 people whose levels would be expected to drop below normal under those trial conditions (my arithmetic, not a label statement). Real-world rates depend on dose, duration and individual risk, which is why the monitoring schedule matters.
Alcohol, other medicines, and interactions
The label says alcohol “potentiates the effect of metformin on lactate metabolism,” and warns against excessive intake. See our broader alcohol and blood sugar guide for the other side of that conversation, including low blood sugar later on.
The interactions table in the label names four groups to mention to your prescriber and pharmacist: carbonic anhydrase inhibitors such as topiramate (may increase the risk of lactic acidosis); drugs that reduce metformin clearance, with examples including ranolazine, vandetanib, dolutegravir and cimetidine; insulin or insulin secretagogues (higher risk of low blood sugar); and drugs that tend to raise blood sugar, which may lead to loss of control. The practical point is not to memorize the list. It is to give your pharmacist your complete medicine list, including over-the-counter products and supplements, every time something is added.
Pregnancy, breastfeeding and planning ahead
The label says limited data in pregnant women are not sufficient to determine a drug-associated risk, and that poorly controlled diabetes in pregnancy carries risks for mother and fetus. It says metformin is present in human milk in limited published studies, with insufficient information to determine effects on the breastfed infant. It also has a patient-counseling note for females of reproductive age: treatment may cause ovulation in some premenopausal women who are not ovulating, which may lead to unintended pregnancy. If you could become pregnant or are planning a pregnancy, that is a conversation to have with your prescriber early, ideally before conceiving.
How glucose tracking fits in
Medication labels talk in averages; your own numbers show how you are doing. Our guide to reading CGM data and the post-meal glucose tracker are tools for keeping a clean record to bring to your visit. They are not a way to adjust a prescription on your own. A useful log notes the date, the time of your medicine, meals, any stomach symptoms, and any readings that worried you. Hand that to your prescriber and let them interpret it.
Questions to bring, by situation
These are not instructions. They are prompts for your appointment.
If you were just prescribed metformin
Which form am I getting, and why that one? What stomach side effects should I expect, and when should I call? When will my kidney function and B12 be checked? Do any of my other medicines or supplements interact? What should I tell the pharmacist?
If you have stomach side effects
How long is too long to wait before calling? Is there a different form or approach worth discussing? Could another reason explain the symptoms? Please decide with your prescriber; do not change anything on your own.
If you have a scan, surgery or procedure coming up
Whom do I tell that I take metformin? Who decides what happens to it around the procedure and for how long? When will my kidney function be rechecked afterward?
If you are over 65, have kidney or liver issues, or drink alcohol
Which of the risk factors on the label apply to me? How often should my labs be checked? What symptoms should send me to urgent care?
If you are pregnant, planning a pregnancy or breastfeeding
What does my plan look like before conception, during pregnancy and while nursing? Who coordinates between my diabetes team and my obstetric team?
If you are comparing metformin with supplements you have seen online
Ask your prescriber whether any supplement is safe with your medicines. A supplement is not a replacement for a prescribed medicine, and a headline is not a study. Our existing pages on berberine and metformin and whether berberine is “nature’s Ozempic” explain what is and is not known, and none of it is a reason to change a prescription.
Common mistakes
Stopping or skipping because of stomach upset without calling. Bring it to your prescriber. The label and Medication Guide both treat persistent or late-onset side effects as something to report.
Assuming “safe for decades” means no monitoring. The label asks for periodic kidney function and B12 checks.
Forgetting to mention metformin before a scan or surgery. The label ties both to risk.
Treating the boxed warning as a reason for panic. The label and the Endotext review both describe lactic acidosis as rare. The point is to know the risk factors and symptoms.
Mixing in alcohol without understanding the label. The label specifically warns about excessive intake.
Using a supplement as a replacement. No supplement has the label, trial program and monitoring that a prescription medicine has. See the berberine pages above, and talk to your prescriber first.
Judging the medicine by one number. The label’s trial averages do not predict your result.
Myth versus fact
Myth: Metformin forces your pancreas to make more insulin. Fact: The label says insulin secretion remains unchanged; the effect is mainly on liver glucose output, gut absorption and sensitivity.
Myth: Metformin damages your kidneys. Fact: The label says it is cleared by the kidneys and is contraindicated when kidney function is severely reduced, which is why eGFR is checked. The label describes kidney function as a safety factor because metformin is cleared by the kidneys, which is a different statement from saying the medicine damages them. I am not a clinician, and my reading of the label was not exhaustive; ask yours.
Myth: If you are on metformin you never need to worry about B12. Fact: The label reports lower B12 in about 7% of trial patients and recommends monitoring.
Myth: Metformin is only for people who are overweight. Fact: The main adult trial in the label enrolled obese adults, but the indication in the label is for adults with type 2 diabetes, not for a weight category.
Myth: A natural product is the same as metformin. Fact: Prescription labels summarize specific trials; supplements are not required to have them. Ask your prescriber before combining anything.
Twelve questions to ask your prescriber or pharmacist
- Why metformin for me, and how does it fit with the rest of my plan?
- Which form am I getting, and what is different about it?
- What side effects should I expect, and when should I call you?
- Which of the lactic acidosis risk factors on the label apply to me?
- What was my last eGFR, and when will it be checked again?
- When should my vitamin B12 be tested, and what would you do with the result?
- Does anything on my medicine list, including supplements, interact?
- What is your plan for scans with contrast dye or for surgery?
- What do I do about alcohol?
- Is there a sick-day plan for me, and who do I call?
- If I am pregnant or planning to be, who coordinates my care?
- What numbers or symptoms should I bring to our next visit?
Frequently asked questions
What is metformin used for?
The label I read says it is an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and it also describes use in young people aged 10 to 16 in its trial data.
How does metformin work?
Per the label, it reduces glucose production in the liver, reduces glucose absorption in the gut and improves insulin sensitivity. The label says insulin secretion remains unchanged.
What are the common side effects?
In the label’s U.S. trial, diarrhea (53% vs 12% on placebo), nausea or vomiting (26% vs 8%), gas (12% vs 6%), weakness (9% vs 6%), indigestion (7% vs 4%), abdominal discomfort (6% vs 5%) and headache (6% vs 5%). The Medication Guide says these generally go away over time and to tell your doctor if they last or return.
What is lactic acidosis?
A rare but serious buildup of lactic acid. The label carries a boxed warning, says onset is often subtle, and lists risk factors including kidney impairment, certain drugs, age 65 or older, contrast dye, surgery, hypoxic states, heavy alcohol use and liver impairment. Get urgent medical help for the symptoms the Medication Guide lists.
Can metformin affect my kidneys?
The label says it is contraindicated when eGFR is below 30, says starting is not recommended when eGFR is 30 to 45, and says to obtain an eGFR at least annually. Ask your prescriber how often yours is checked.
Does metformin lower vitamin B12?
The label reports subnormal B12 in about 7% of patients in trials and recommends monitoring. See our metformin and B12 guides.
Is it safe to drink alcohol on metformin?
The label warns that alcohol potentiates metformin’s effect on lactate metabolism and warns against excessive intake. Ask your prescriber what applies to you.
What about contrast dye or surgery?
The label addresses both and says to tell the imaging or surgical team. Your prescriber and those teams decide what to do with your medicine.
Can I take metformin if I am pregnant or breastfeeding?
The label says limited data are not sufficient to determine pregnancy risk, and that metformin is present in human milk. Decisions belong with your prescriber and obstetric team.
Can berberine replace metformin?
This page does not support swapping a prescribed medicine for a supplement. Talk to your prescriber; see our berberine pages for what is known.
Sources
- DailyMed: metformin hydrochloride tablets label (revised June 2026, one generic manufacturer)
- Feingold KR, Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes, Endotext (updated December 29, 2025)
MedlinePlus, NIDDK and the ADA Standards of Care could not be opened with the tools available to me, so I did not quote them. Labels change; check the one that came with your prescription.
About the author: Charles Kirkland is the founder of Metabolic Clarity Labs and author of The Journey Back. He is not a physician. This is general education, not a medically reviewed treatment plan.
Sources checked October 31, 2026. Discuss personal decisions with a qualified clinician. Do not start, stop, or change prescribed treatment based on this article.
Leave a Reply